6533b85cfe1ef96bd12bcb90
RESEARCH PRODUCT
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights
Ali A. RizviAli A. RizviMartin PraznyNikolaos PapanasRizzo ManfrediManfredi RizzoAnca Pantea Stoiansubject
Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Indexdescription
The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COVID-19 severity and mortality, and accumulating evidence suggests that IBTs may favorably alter the clinical course of SARS-CoV-2 infection due to their inherent mechanisms of action. Further research into prognostic variables associated with various antidiabetic treatment regimens, and in particular the IBT, in patients with T2DM affected by the COVID-19 pandemic is therefore warranted.
year | journal | country | edition | language |
---|---|---|---|---|
2020-07-03 |